Group schema-focused therapy enriched with psychomotor therapy for older adults with personality disorders in specialized mental health care: a (cost-) effectiveness study

Group schema-focused therapy enriched with psychomotor therapy for older adults with personality disorders in specialized mental health care: a (cost-) effectiveness study - Cost-effectiveness of group schema-focused therapy in geriatric psychiatry

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON47231

Enrollment

140

Registered

2018-10-17

Start date

2017-09-05

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Personality disorder

Interventions

Twenty sessions of group SFT+PMT delivered in groups of 4 through 8 older patients over a 6-month period.

Cost-effectiveness

Geriatric psychiatry

Personality disorder

Psychotherapy

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Age: 60 years or older - Cluster B or C personality disorder - Mentally able to adhere to the group schema-focused treatment schedule and to fill out the schema (-mode) questionnaires - Informed consent for the study

Exclusion criteria

Exclusion criteria: - Severe mental illness, including current bipolar disorder or psychosis, or substance abuse disorder needing clinical detoxification. - An established neurodegenerative disorder or cognitive impairment defined as a Montreal Cognitive Assessment (MoCA) sum score below 24 points. - Prior schema-focused therapy, received in the previous year or during the present episode of illness. - Immediate suicide risk interfering with adequate treatment delivery.

Design outcomes

Primary

Measure	Time frame
Primary outcome is general psychological distress (Brief Symptom Inventory; BSI-53). Cost-effectiveness analysis will be performed from a societal perspective (based on EQ-5D-5L and structured cost-interviews).	—

Secondary

Measure	Time frame
Secondary outcome measures are: quality of life and psychotropic drug use.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)